Currently, Faslodex is approved only for use in patients who have metastatic breast cancer.

FORBES: Magazine Article

Faslodex works by inhibiting the estrogen receptors on the surface of cancer cells.

FORBES: Searching For An Heir To Tamoxifen

Osborne has been studying another AstraZeneca drug, Faslodex, in metastatic breast cancer.

FORBES: Searching For An Heir To Tamoxifen